BOSTON & PERTH, Australia--(BUSINESS WIRE)--April 3, 2006--Global bio-nanotech company pSivida Limited (NASDAQ:PSDV - News; ASX:PSD - News; Xetra:PSI - News) today announced additional two year trial results of Bausch & Lomb’s two randomized trials to evaluate the safety and efficacy of the Retisert(TM) implant in releasing fluocinolone acetonide in the management of Diabetic Macular Edema (DME). Bausch & Lomb, exclusive licensee of Retisert(TM) from pSivida conducted the studies in hospitals in the United States involving 277 patients. The trial results were presented at the prestigious 6th International Symposium on Ocular Pharmacology and Therapeutics in Berlin that commenced on 30 March 2006 http://www.kenes.com/isopt/index.asp.
